No Data
The "A+H" profit effect is prominent! Contemporary Amperex Technology and Hengrui Pharmaceuticals are leading, with the three essentials for a bull stock: top pricing, oversubscription, and a significant price increase at the opening.
There are three reasons why Hengrui Pharmaceuticals has been able to perform so well: first, the company's quality is quite good; second, since 2025, a "bull market for innovative drugs" has unfolded in the Hong Kong stock market; third, the profitability effect of Hong Kong stock IPOs continues to stand out.
Major firm rating | Target Price of HKD 82! CITIC SEC initiates coverage of Weisheng Pharmaceuticals (2561.HK) with a "Buy" rating.
CITIC SEC has released a research report, initiating coverage of Weisheng Pharmaceutical (2561.HK) with a "Buy" rating and a Target Price of 82 HKD. The report points out that the company is an innovative pharmaceutical enterprise in the endocrine field, currently possessing three products introduced by Ascendis Pharma; Ascendis Pharma is a deep partner of the company, recently with a Market Cap of around 10 billion USD on the US stock market, reflecting the market's high recognition of its core technology platform. According to the company's prospectus, the fastest R&D progress is with Lonapegsomatropin (long-acting growth hormone), and the company expects to launch it in H2 2025.
Hong Kong stock market news | Weisheng Pharmaceutical-B (02561) rises over 5% as the drug Neopeptide for treating achondroplasia completes Phase II clinical trials in China.
Weisheng Pharmaceutical-B (02561) rose over 5%, as of the time of writing, up 5.39%, priced at 46.9 Hong Kong dollars, with a trading volume of 2.1721 million Hong Kong dollars.
JV incubation, how to nurture the first Innovative Drugs stock in Hong Kong by 2025? | Interview with Fu Shan, Managing Partner of Weifu Capital.
Why choose this model to incubate Weisheng Pharmaceutical? What are the underlying considerations of the industry beyond capital?
Major banks rating丨Futrue Financial: Initiating coverage on Weisheng Pharmaceutical (2561.HK) with a "Buy" rating and a Target Price of HKD 82.
Frost & Sullivan released a research report, covering Weisheng Pharmaceutical (2561.HK) for the first time. The report indicates that Weisheng Pharmaceutical is a biopharmaceutical company approaching the commercialization stage, focusing on endocrine diseases in the Greater China region. It currently has three drugs in development, introduced from the Danish pharmaceutical company Ascendis, and holds exclusive licensing rights without sales sharing. Its core product, Lonpeiz Growth Hormone, has been launched in the United States and Europe and has the potential to become the best-in-class long-acting growth hormone, with China's BLA expected to be approved in the second half of 2025. The company was rated as "Buy" based on the DCF model.
Viasheng Pharmaceutical (02561) roadshow summary: Innovative verification technology supports the enhancement of commercialization certainty for the product pipeline.
Recently, Weisheng Pharmaceutical (02561) had in-depth discussions with investors regarding the company's fundamentals and the development status of its core product pipeline.
